Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Gilead's elvitegravir has met its primary efficacy endpoint (non-inferiority in treatment-experienced patients) in the first head-to-head trial against the already marketed integrase inhibitor Isentress. If approved, standalone elvitegravir will face fierce competition from established therapies in this patient population.
Published By Datamonitor
|
24 Mar 2011 |
|
Expert View
|
Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. For another year running, developments in multiple sclerosis (MS) treatment research dominated proceedings. Below are the highlights of the conference's coverage of new multiple sclerosis drugs.
Published By Datamonitor
|
03 May 2011 |
|
Expert View
|
Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. Developments in late-stage pipeline agents for Parkinson's disease were a key talking point at AAN 2011. Below are the highlights of the conference's coverage of new Parkinson's drugs.
Published By Datamonitor
|
03 May 2011 |
|
Expert View
|
On May 2, 2011, Teva announced that it was to acquire US-based Cephalon for $6.8bn. The consolidation of Cephalon will accelerate Teva's strategy of an increased presence in the branded pharmaceutical market. Given that Cephalon's pipeline is heavily focused on oncology, an area in which Teva has no major branded presence, the deal will also prompt future therapeutic diversification.
Published By Datamonitor
|
18 May 2011 |
|
CommentWire
|
Phase III data show that treatment with Xgeva improved bone metastasis-free survival for advanced castrate-resistant prostate cancer patients, and the drug could now become the first therapy approved to delay the onset of metastasis. This would boost sales of Xgeva, but uptake may be restricted due to the high cost of treatment.
Published By Datamonitor
|
20 May 2011 |
|
Expert View
|
Datamonitor recently attended the 30th Annual Scientific Meeting of the American Pain Society in Austin, Texas, held over May 19-21, 2011. Below are the highlights of the conference's coverage of anti-NGF antibodies in chronic pain.
Published By Datamonitor
|
03 Jun 2011 |
|
CommentWire
|
Swiss drugmaker Merck Serono has announced the discontinuation of additional trials for cladribine and the withdrawal of the product from the Russian and Australian markets, showing that the firm has decided to cut its losses and accept a costly failure. The decision to discontinue a once potentially blockbusting therapy is a huge setback for Merck and its multiple sclerosis portfolio.
Published By Datamonitor
|
22 Jun 2011 |
|
Expert View
|
Pipeline antidiabetic drug Bydureon has overcome another obstacle to approval, with developers Amylin, Eli Lilly, and Alkermes announcing that supratherapeutic doses of the product do not cause a change in heart rhythm by affecting the QT interval. These results pave the way for the resubmission of Bydureon in the US later in 2011.
Published By Datamonitor
|
12 Jul 2011 |
|
CommentWire
|
Bristol-Myers Squibb has announced that the FDA has approved the subcutaneous formulation of its marketed intravenous biologic therapy Orencia. Based on primary research, Datamonitor anticipates a high degree of patient shifting from intravenous Orencia to the subcutaneous formulation and forecasts sales of the latter to reach $695m by 2019 in the US.
Published By Datamonitor
|
01 Aug 2011 |
|
Expert View
|
Teva has announced the EU approval of NOMAC/E2, the first monophasic contraceptive with natural estrogen. The perceived increased safety of natural estrogen and a global launch will drive sales of the product, making it a leading hormonal contraceptive brand. To maximize its potential, however, Teva needs to show improved safety over synthetic estrogen contraceptives in post-marketing studies.
Published By Datamonitor
|
03 Aug 2011 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.